<>
Major Rugby has issued a nationwide recall for multiple lots of Levothyroxine Sodium tablets, according to safety notices distributed to the supply chain. The affected medication, which is prescribed to treat hypothyroidism and other thyroid conditions, is being recalled because the tablets are subpotent, meaning they contain less active ingredient than stated on the product labeling. Patients who rely on the daily hormone therapy are being urged to check their pill bottles against specific lot numbers and expiration dates to determine if their prescription is impacted.
The recall encompasses 12 different product variations distributed under the Major and Cardinal brands. According to the company’s notice, the affected batches were distributed nationwide starting in January 2025. The impacted products cover a wide range of dosages, spanning from 25 mcg to 150 mcg, and include various packaging formats such as 100-count bottles and smaller blister configurations.
Affected Dosages and Lot Identification
Identifying the recalled medication requires checking specific lot numbers and expiration dates printed on the packaging. For the 25 mcg tablets, the recall includes 100-count bottles with lot number N02212 and an expiration date of 07/2026. Smaller 10-count blister configurations for the 25 mcg strength are also affected, specifically carrying bag lot numbers N02212A and N02212B with the same 07/2026 expiration date.
Other specific batches identified in the recall include:
- 50 mcg (100-count): Lot # N02200, expiration date 10/2026; smaller blister packs carry bag lots # N02200A and N02200B.
- 75 mcg (100-count): Lot # N02172, expiration date 07/2026.
- 88 mcg variants: Lot numbers include # N02310 (expiration date 01/2027) alongside # N02296 and # N02288 (expiration date 12/2026).
- 112 mcg (100-count): Lot # N02203, expiration date 09/2026.
- 125 mcg (100-count): Lot # N02266, expiration date 11/2026; corresponding blister bag lots are # N02266A and # N02266B.
- 150 mcg (100-count): Lot # N02167, expiration date 07/2026; corresponding blister bag lots are # N02167A and # N02167B.
Clinical Implications of Subpotent Thyroid Medication
Levothyroxine is a narrow therapeutic index drug, meaning that small variations in dosage can lead to noticeable shifts in a patient’s clinical status. The medication is used to replace or provide additional thyroid hormone for individuals diagnosed with hypothyroidism, a condition where the thyroid gland does not produce enough hormones to support normal bodily functions. It is also prescribed to manage certain types of thyroid enlargements and specific thyroid cancer cases.
Because the recalled batches are classified as subpotent, patients taking these specific pills may experience a gradual decline in effective hormone levels over time if their dose is delivering less active pharmaceutical ingredient than intended. While the manufacturer’s communication indicates that the issue is not categorized as an acute safety hazard, health guidelines advise against continuing to ingest recalled products without professional oversight.
Next Steps for Consumers and Supply Chain
Consumers who discover they have a recalled batch of Levothyroxine Sodium in their medicine cabinets are advised to stop using the specific tablets and return them to the point of purchase. Regulatory and industry procedures focus on the controlled removal of subpotent items from the distribution chain to prevent prolonged under-dosing.
Patients are encouraged to consult their prescribing physician or healthcare provider to review their current therapy. A doctor can evaluate whether an alternative prescription or a temporary adjustment in monitoring is necessary to ensure thyroid hormone levels remain stable within the target therapeutic range.